Abstract: Background: Psoriasis is a chronic inflammatory skin disease that often progresses with nail alterations. It is suspected that there is a correlation between nail psoriasis and enthesitis of the distal interphalangeal joint, seeming to serve as a predictor. Objectives: To analyze the profile of patients with nail psoriasis and correlate the presence of nail alterations with psoriatic arthritis, quality of life, extent of psoriasis and the histopathology of the nail. Methods: An observational cross-sectional study with 40 patients with a diagnosis of psoriasis and without systemic treatment. The patient profile was researched, including quality of life and evaluated for the presence of psoriatic arthritis. The severity of the skin psoriasis and the presence of nail lesions were evaluated. Nail fragments were collected and analyzed through clipping. It obtained 100% of positivity for psoriasis in the histopathology exam of the nail plate. Results: Of the 40 patients, 65% were diagnosed with nail psoriasis. Suggestive findings of psoriatic arthritis in hands were present in 33%, being more frequent in those with nail alteration (p = 0.01). In 92.3% of patients diagnosed with psoriatic arthritis in the hands there was some nail injury. The most frequent injuries were pitting and onycholysis. Conclusions: Patients with nail psoriasis are usually men, with worse quality of life and higher chance of psoriatic arthritis. The correlation between the nail involvement of psoriasis and psoriatic arthritis in hands confirms the association between these two forms. The clinical diagnosis of nail psoriasis did not correlate with the histological diagnosis.

Intravascular papillary endothelial hyperplasia is a benign vascular lesion caused by proliferation of endothelium. It is reactive to thrombotic or inflammatory stimuli in the vessel wall.We report the case of a 14-yearold male patient with a violet-colored erythematous tumoral lesion of progressive growth in the occipital region. The diagnosis of intravascular papillary endothelial hyperplasia (IPEH) was confirmed by clinical and histopathological findings. Total lesion exeresis was performed with no recurrence up to date. IPEH presents clinical importance due to its clinical and histological resemblance to angiosarcoma. In order to differentiate it from angiosarcoma, distinguishing features of the benign disease should be considered, such as lack of cellular atypia and rare mitotic activity.Prognosis is good.

The Peutz-Jeghers syndrome (PJS) is an autosomal-dominant hamartomatous polyposis syndrome characterized by mucocutaneous pigmentation, gastrointestinal polyps and the increased risk of multiple cancers. The causative point mutation in the STK11 gene of most patients accounts for about 30% of the cases of partial and complete gene deletion. This is a report on a girl with PJS features, learning difficulties, dysmorphic features and cardiac malformation, bearing a de novo 1.1 Mb deletion at 19p13.3. This deletion encompasses at least 47 genes, including STK11. This is the first report on 19p13.3 deletion associated with a PJS phenotype, as well as other atypical manifestations, thereby implying a new contiguous gene syndrome.

OBJETIVO: Realizar uma revisão da literatura sobre neurofibromatose tipo 1 (NF1) em crianças e adolescentes, enfatizando as manifestações clínicas. FONTES DE DADOS: Artigos publicados, indexados na base de dados Medline e publicados entre 1998 a 2007, buscados pelos seguintes termos: "neurofibromatosis type 1", "neurofibroma", "von Recklinghausen" e "optic pathway gliomas". SÍNTESE DOS DADOS: A NF1 é uma doença genética autossômica dominante, crônica e progressiva, com incidência de 1/2.000 a 1/7.800 nascidos vivos. Tem sido observada em diferentes partes do mundo, em todas as raças e nos dois sexos. Metade dos casos representa mutações novas. A taxa de mutação para o gene NF1 é de 1/10.000, a qual se deve ao fato do gene ser grande e possuir estrutura interna atípica, que predispõe a deleções e mutações. O diagnóstico presuntivo da NF1 é feito por critérios clínicos. As três principais manifestações - neurofibromas, manchas café-com-leite e nódulos de Lisch - ocorrem em mais de 90% dos pacientes até a puberdade. CONCLUSÕES: Os cuidados com os pacientes com NF1 devem antecipar as principais complicações e oferecer um tratamento precoce. No aconselhamento genético, é importante informar pais e familiares a respeito do panorama geral da doença e suas possíveis complicações, enfatizando que a maioria dos pacientes apresenta vida saudável e produtiva.

OBJECTIVE: To review clinical and diagnostic features of neurofibromatosis type 1 (NF1) in children and adolescents. DATA SOURCES: Articles published from 1998 to 2007 and retrieved by the words "neurofibromatosis type 1"; "neurofibroma", "von Recklinghausen" and "optic pathway gliomas" in Medline database. DATA SYNTHESIS: NF1 is a chronic and progressive autosomal dominant disorder with an incidence of 1/2,000 to 1/7,800 live births. There is no racial, geographic or gender preference. Half of the cases represent new mutations, and the mutation rate for NF1 gene is 1/10.000. The high mutation rate of NF1 may reflect the fact that the gene is large and/or that it has an unusual internal structure, predisposing it to deletions and other mutations. The presuntive diagnosis of NF1 is made on clinical basis. The three main features - neurofibromas, café-au-lait spots and Lisch nodules - are present in more than 90% of all affected patients until puberty. CONCLUSIONS: The mainstay of care for patients with NF1 is anticipatory guidance and early detection and treatment of disease complications. Counseling of patients and their families should provide a realistic overview of possible clinical complications, while emphasizing that most individuals with NF1 have healthy and productive lives.

OBJETIVO: Avaliar a prevalência de neurofibroma plexiforme em crianças e adolescentes com neurofibromatose tipo 1 e seu potencial de transformação maligna. MÉTODOS: Estudo retrospectivo realizado através da análise do banco de dados do Centro Nacional de Neurofibromatose, coletado nos seguintes serviços de referência entre 1996 e 2004: Instituto de Dermatologia Prof. Rubem David Azulay da Santa Casa de Misericórdia do Rio de Janeiro, Instituto de Pediatria e Puericultura Martagão Gesteira da Universidade Federal do Rio de Janeiro e Departamento de Imunologia e Microbiologia da Faculdade de Medicina de Teresópolis. RESULTADOS: Nesse período, foram atendidos 104 pacientes com idade de 1 a 17 anos e diagnóstico clínico de neurofibromatose tipo 1, sendo 53 do sexo masculino e 51 do sexo feminino. Destes, 28 pacientes (15 masculinos e 13 femininos) apresentaram neurofibroma plexiforme (26,9%). Divididos por faixa etária, observou-se 21,42% (seis) entre 1 e 5 anos; 35,71% (10) entre 6 e 12 anos e 42,85% (12) entre 13 e 17 anos. Dos 104 pacientes estudados, dois evoluíram para tumor maligno da bainha do nervo periférico (1,92%). CONCLUSÕES: Os neurofibromas plexiformes são manifestações relativamente comuns em pacientes com neurofibromatose tipo 1 e podem ser causa de aumento significativo da morbimortalidade entre os pacientes. Concluímos, em nosso estudo, que a freqüência de neurofibroma plexiforme e de seu potencial de malignização na população observada está em conformidade com dados da literatura internacional.

OBJECTIVE: To assess prevalence of plexiform neurofibroma in children and adolescents with type I neurofibromatosis and its malignant potential. METHODS: A retrospective study was conducted through analysis of the database at Centro Nacional de Neurofibromatose [Brazilian Neurofibromatosis Center], collected from the following reference services between 1996 and 2004: Instituto de Dermatologia Prof. Rubem David Azulay da Santa Casa de Misericórdia do Rio de Janeiro, Instituto de Pediatria e Puericultura Martagão Gesteira da Universidade Federal do Rio de Janeiro and Department of Immunology and Microbiology at Faculdade de Medicina de Teresópolis. RESULTS: Over that period, 104 patients aged between 1-17 years were admitted with clinical diagnosis of type I neurofibromatosis. Of these, 53 were male and 51 were female, and 28 patients (15 male and 13 female) had plexiform neurofibroma (26.9%). Division by age group resulted in 21.42% (six) between 1-5 years; 35.71% (10) between 6-12 years and 42.85% (12) between 13-17 years. Of the 104 patients, two developed a malignant peripheral nerve sheath tumor (1.92%). CONCLUSIONS: Plexiform neurofibromas are relatively common manifestations in patients with type I neurofibromatosis and may be a cause of significant increase in morbidity and mortality among patients. In this study, we conclude that frequency of plexiform neurofibroma and its malignant potential in the population studied is in agreement with data from the international literature.